Celcuity Inc Stock News

Celcuity Inc. (NASDAQ:CELC ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor Go

MINNEAPOLIS, MN/ ACCESSWIRE / November 3, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, tod

Celcuity Inc. (NASDAQ:CELC ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder, Chairman & Chief Executi

MINNEAPOLIS, MN / ACCESSWIRE / August 4, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today an

The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among

The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, th

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pati

Celcuity Inc. (NASDAQ:CELC ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder, Chairman & Chief Executive

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pat

Celcuity's (CELC) CEO Brian Sullivan on Q4 2021 Results - Earnings Call Transcript

The FDA has granted Fast Track designation to Antares Pharma Inc''s (NASDAQ: ATRS ) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The

Celcuity Inc (CELC) shares closed today 11.9% higher than it did at the end of yesterday. The stock is currently up 37.6% year-to-date, up 17.9% over the past 12 months, and down 11.8% over the past five years. Today, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 1.0%. Trading Activity Shares traded as high as $13.89 and as low as $12.00 this week.Shares closed 57.3% below its 52-week high and 61.1% above its 52-week low.Trading volume this week was 22.9% lower than the 10-day average and 30.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Industrials industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -228.5% The company's stock price performance over the past 12 months beats the peer average by -158.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Celcuity Inc. (NASDAQ:CELC) has earned an average rating of Buy from the seven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings []